摘要
肠易激综合征(irritable bowel syndrome,IBS)是一种常见的功能性肠道疾病,发病率较高,严重影响患者的生活质量。本病病因和发病机制复杂,肠道感染、菌群紊乱、黏膜免疫炎症反应、脑-肠轴功能紊乱、胃肠道动力异常、内脏高敏性和精神心理异常等多种因素参与发病。目前,IBS诊断主要基于症状标准,随着基础研究和临床研究的日渐深入,其潜在生物标记物受到关注。本文就IBS诊断方法及其治疗药物的研究现状、临床疗效及安全性作一综述。
Irritable bowel syndrome(IBS)is one of the most common functional gastrointestinal disorders with high incidence and serious impact on the quality of patients’lives.The etiology and pathogenesis of IBS are complex,gastrointestinal infection,intestinal flora disorder,mucosal immune-inflammatory responses,dysfunction of the brain-gut axis,abnormal intestinal motility,visceral hypersensitivity,and mental disorder are associated with IBS.Currently,the diagnosis of IBS is mainly based on symptom.With the advances in basic and clinical research,potential biomarkers have attracted attention.This paper summarizes the diagnostic methods,as well as the research status,clinical efficacy,and safety concern of medication.
作者
张洁
顾妍晶
樊晓明
郭传勇
伍建业
ZHANG Jie;GU Yan-jing;FAN Xiao-min;GUO Chuan-yong;WU Jian-ye(Department of Gastroenterology,Putuo People's Hospital,Tongji University School of Medicine,Shanghai 200060,China;Department of Gastroenterology,Shanghai Tenth People’s Hospital of Tongji University,Shanghai 200072,China;Shanghai Tenth Hospital,School of Clinical Medicine of Nanjing Medical University,Shanghai 200072,China;Department of Gastroenterology,Jiangsu Province Changzhou 3th People’s Hospital,Changzhou 213000,Jiangsu,China;Department of Gastroenterology,Jinshan Hospital of Fudan University,Shanghai 201508,China)
出处
《世界临床药物》
CAS
2019年第5期302-309,共8页
World Clinical Drug
基金
国家自然科学基金项目(编号:81670472
81700502
81800538
81672344)
上海市卫生健康委员会优青计划项目(编号:2017YQ041)
上海市科学技术委员会扬帆计划(编号:18YF1420000)
上海市金山区重点临床学科建设项目(编号:JSZK2015A06)
上海市普陀区科学技术委员会卫生系统创新计划(ptkwws201901)
关键词
肠易激综合征
诊断
生物标记物
呼出气体
药物治疗
irritable bowel syndrome
diagnosis
biological markers
exhaled gas
pharmaco therapy
